Multiple myeloma

N Engl J Med. 2004 Oct 28;351(18):1860-73. doi: 10.1056/NEJMra041875.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / adverse effects
  • Boronic Acids / pharmacology
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Combined Modality Therapy
  • Disease Progression
  • Humans
  • Lenalidomide
  • Multiple Myeloma / complications
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / physiopathology
  • Multiple Myeloma / therapy*
  • Paraproteinemias / genetics
  • Paraproteinemias / physiopathology
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use
  • Pyrazines / adverse effects
  • Pyrazines / pharmacology
  • Pyrazines / therapeutic use*
  • Remission Induction
  • Stem Cell Transplantation*
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives*
  • Thalidomide / pharmacology
  • Thalidomide / therapeutic use*

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Protease Inhibitors
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Lenalidomide